Hervolution Therapeutics

Hervolution Therapeutics is a biotechnology company based in Copenhagen, Denmark, with operations in the United States. Founded in 2018, the company focuses on developing novel immunotherapies that target Human Endogenous Retroviruses (HERVs) for diseases related to aging, cancer, and neurodegeneration. Hervolution aims to unlock the therapeutic potential of HERVs, which were previously considered undruggable, by using a proprietary platform to make these antigens visible to the immune system.

The company's pipeline includes off-the-shelf immunotherapies for various conditions, including prostate, pancreatic, and breast cancers, as well as multiple sclerosis and amyotrophic lateral sclerosis. Hervolution has raised $11.7 million in Series A funding to support its clinical development efforts, with plans to advance its leading program in 2024. The company serves the healthcare and pharmaceutical sectors, focusing on patients with cancer and age-related diseases, and operates a B2B business model.